Top Qs
Timeline
Chat
Perspective

Maridebart cafraglutide

Experimental medication From Wikipedia, the free encyclopedia

Remove ads

Maridebart cafraglutide (also known as MariTide;[1] developmental name AMG 133) is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor (GLP-1R) and an antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR). Namely, MariTide consists of a monoclonal antibody against GIPR conjugated to two peptidic GLP-1R agonist molecules via amino acid linkers.[2] In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested.[3][4][5]

Quick facts Clinical data, Other names ...
Remove ads

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads